Close Menu

NEW YORK – Qiagen's newly promoted, if temporary, CEO Thierry Bernard this week took on the unenviable task of assuaging investors' fears in the wake of a tumultuous month in which the company announced that it would end development of next-generation sequencing instruments, compounding existing sales weakness in China that caused Qiagen to deliver lower-than-expected revenues for the third quarter and reduce its fourth quarter expectations.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.